Orrick Advises Cortexyme on $125 Million Private Placement

February.11.2020

Orrick has advised San Francisco-based biopharmaceutical company Cortexyme (Nasdaq: CRTX) on its $125 million private placement of common stock. Cortexyme issued 2,500,000 shares of common stock for a purchase price of $50.00 per share. 

Cortexyme plans to use the net proceeds from the private placement to advance clinical development, as well as for general corporate purposes. BofA Securities and Jefferies served as placement agents for the private placement, and Canaccord Genuity LLC, JMP Group LLC and LifeSci Capital LLC served as financial advisors.

The Orrick team advising Cortexyme included Scott Iyama, Niki Fang and Brigid McCurdy. Orrick has been advising Cortexyme since its Series A financing and counseled the company on its IPO last year. Orrick continues to counsel the company on various aspects of its business, including corporate and trademark matters.